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Our study was initiated by previous isolation of 30
imipenem-resistant, gram-negative rods from 7 of 16 U.S.
rivers sampled from 1999 to 2001. Imipenem hydrolysis
was detected in 22 of those isolates identified as
Enterobacter asburiae. Random amplified polymorphism
DNA analysis showed that these E. asburiae isolates were
genetically indistinguishable. An identical clavulanic
acid–inhibited β-lactamase IMI-2 was identified from each
isolate that shared 99% and 97% amino acid identity with
the chromosome-encoded β-lactamases IMI-1 and NmcA,
respectively, from E. cloacae clinical isolates. The blaIMI-2
gene was located on a self-transferable 66-kb plasmid.
Sequence analysis of a cloned 5.5-kb DNA fragment
obtained from 1 of the imipenem-resistant E. asburiae iso-
lates identified an upstream LysR-type regulator gene that
explained inducibility of IMI-2 expression. β-Lactamase IMI-
2 is the first inducible and plasmid-encoded carbapene-
mase. Identification of clonally related E. asburiae isolates
from distant rivers indicates an environmental and enter-
obacterial reservoir for carbapenemase genes.
C
arbapenems, such as imipenem and meropenem, are
the most potent β-lactam antimicrobial drugs for
avoiding resistance in gram-negative rods. Resistance to
carbapenems is rare in Enterobacteriaceae and may be
mediated by 3 mechanisms: hyperproduction of an AmpC-
type cephalosporinase combined with decreased drug per-
meability through the outer membrane, decreased affinity
of penicillin-binding proteins that constitute target proteins
for carbapenems, and carbapenem-hydrolyzing β-lacta-
mases (1–3). These rare carbapenemases may be either
plasmid-mediated metallo-β-lactamases (IMP- and VIM-
type) or chromosomally encoded and clavulanate-inhibited
enzymes (NmcA, IMI-1, Sme-1/Sme-2) (2,4–9). The latter
group of enzymes shares consistent percentage of identity
and belongs to the Ambler class A of β-lactamases (2,10).
Very recently, plasmid-mediated and clavulanate-inhibited
carbapenemases have been reported as a source of nosoco-
mial infections in U.S. hospitals (11–15). 
While the role of animals in the emergence of clinical-
ly important, antimicrobial-resistant strains has been
extensively shown (e.g., in Salmonella spp.), the role of
aquatic environment as a reservoir of antimicrobial-resist-
ance genes is less established (16–21). A recent study
described high levels of antimicrobial-resistant strains
from U.S. rivers (22). We identified the imipenem-resist-
ant, gram-negative strains recovered from that study and
analyzed the molecular mechanism involved in carbapen-
em resistance of the imipenem-resistant enterobacterial
strains. Clonally related Enterobacter asburiae strains
were identified in midwestern U.S. rivers. E. asburiae nat-
urally produces a cephalosporinase but no carbapenemase
and may be responsible for nosocomial infections (23).
Here, the strains expressed a novel plasmid-encoded and
clavulanate-inhibited carbapenemase. 
Materials and Methods
Bacterial Isolates
A previous study identified 30 imipenem-resistant,
gram-negative strains out of 1,861 ampicillin-resistant,
gram-negative isolates from 7 out of 16 U.S. rivers that
were sampled from 1999 to 2001 (22). Identification of
these imipenem-resistant isolates was performed by con-
ventional biochemical techniques (API-20E and API-NE
systems [bioMérieux, Marcy-l’Etoile, France]), and con-
firmed by 16S rDNA sequencing (24).
E. asburiae CIP 103358 and E. asburiae CIP 105006
were used as reference strains (Institut Pasteur strain col-
lection, Paris, France). E. cloacae NOR-1 and E. cloacae
1413B were used as strains that produce the chromosome-
encoded, clavulanate-inhibited carbapenemases NmcA
and IMI-1, respectively (5,8). One of the E. asburiae iso-
lates recovered from a river (strain MS7) was used for
cloning experiments. Streptomycin-resistant Escherichia
coli DH10B strain was used in cloning and conjugation
experiments (Life Technologies, Eragny, France).
Antimicrobial Agents and Resistance Study
The antimicrobial agents and their sources were as
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Topeka, Kansas, USAfollows: amoxicillin, ceftazidime, clavulanic acid, and
ticarcillin (GlaxoSmithKline, Nanterre, France); aztreon-
am (Bristol-Myers Squibb, Paris La Defense, France);
cephalothin (Eli Lilly, Saint-Cloud, France); piperacillin
and tazobactam (Lederle, Les Oullins, France); cefotaxime
(Aventis, Romainville, France); imipenem (without cilas-
tatin) (Merck Sharp and Dohme, Paris, France); meropen-
em (AstraZeneca, Paris, France); ampicillin and
streptomycin (Sigma, Paris, France).
MICs were determined by an agar dilution technique on
Mueller-Hinton (MH) agar (Sanofi Diagnostics Pasteur,
Marnes-La-Coquette, France) with an inoculum of 104
CFU per spot (25). Carbapenemase activity was deter-
mined by UV spectrophotometry with culture extracts of
each of the imipenem-resistant, gram-negative rods and
imipenem (100 µmol) as substrate, as reported previously
(26). One unit of enzyme activity corresponded to the
hydrolysis of 1 µmol of substrate per min. Inducibility of
the β-lactamase expression was determined with imipen-
em and cefoxitin as β-lactamase inducers, as described
(27). Briefly overnight culture of each imipenem-resistant
E. asburiae isolate was diluted (1:10) in a prewarmed tryp-
ticase soy broth, allowed to culture in an antimicrobial-free
medium for 2 h, and further cultured for 6 h with cefoxitin
(2–50 mg/L) or imipenem (10–50 mg/L). β-Lactamase
culture extracts were obtained after centrifugation and son-
ication, as detailed (26). 
Nucleic Acid Techniques and Conjugation 
Genotype comparison of the imipenem-resistant E.
asburiae strains was performed by using the random
amplified polymorphism detection (RAPD) technique as
described with primer 6MW (CCGACTCGAG
NNNNNNATGTGG) and primers UBC 245 and UBC 282
(26,28,29). Transfer of the imipenem resistance marker
from each imipenem-resistant E. asburiae isolate to E. coli
DH10B was attempted by using the immobilization filter
mating out technique, as described (26). Briefly, equal vol-
ume (0.1 mL) of overnight cultures of each E. asburiae
isolate and E. coli DH10B were put onto a paper filter that
was placed on an MH agar plate. Twenty-four hours later,
the filter was removed, washed with water (0.2 mL), and
the bacterial suspension was spread onto MH agar plates
containing ampicillin (100 mg/L) and streptomycin (50
mg/L) for selecting transconjugants after 24 h (26).
Plasmid extraction was performed for each E. asburiae
strain and their transconjugants and compared to reference
plasmid sizes of E. coli NCTC 50192 by using the Kieser
technique designed to extract large size plasmids (30,31).
Whole-cell DNA of Enterobacter spp. reference strains
and of an E. asburiae strain MS7 was extracted as
described (26).
Southern hybridization of plasmid DNA (26) of the
transconjugants was performed as described by the manu-
facturer with the ECL nonradioactive kit (Amersham, Les
Ulis, France). An 818–bp internal probe for blaIMI-1 was
obtained by using primers IMI-A (5'-ATAGCCATC-
CTTGTTTAGCTC-3') and IMI-B (5'-TCTGCGAT-
TACTTTATCCTC-3') and standard polymerase chain
reaction (PCR) amplification procedures (5,26). 
Primers designed to hybridize to the ends of the
blaNmcA,  blaIMI-1, and blaSme-1/Sme-2 genes were used for
standard PCR amplification experiments (5,7,8) with plas-
mid DNA of each imipenem-resistant E. asburiae isolate
and of their transconjugants as templates. Cloning experi-
ments were then performed with BamHI restricted whole-
cell DNA of E. asburiae MS7 followed by ligation of
DNA fragments into the BamHI-site of cloning vector
pGB2 (32). Recombinant plasmids were transformed by
electroporation into E. coli DH10B electrocompetent cells
(26). E. coli DH10B harboring recombinant plasmids was
selected on MH agar plates containing ampicillin (100
mg/L) and streptomycin (100 mg/L).
DNA sequencing of both strands of PCR fragments
amplified with the primers for blaIMI-1 and plasmid DNAof
E. asburiae isolates as templates and of the cloned frag-
ment of a recombinant plasmid was determined with an
Applied Biosystems sequencer (ABI377). The nucleotide
sequences and the deduced protein sequences were ana-
lyzed with software available on the Internet from the
National Center for Biotechnology Information Web site
(http://www.ncbi.nlm.nih.gov/BLAST).
Results
Bacterial Identification
Twenty-nine of the 30 imipenem-resistant isolates sub-
stantially hydrolyzed imipenem, i.e., 10.5 ± 1.6 U/mg of
protein of culture extracts. These isolates were a single
Aeromonas hydrophila isolate, 6 Stenotrophomonas mal-
tophilia isolates known to naturally produce carbapene-
mases, and 22 Enterobacter spp. isolates identified as E.
asburiae that were further analyzed.
As reported in Table 1, E. asburiae strains were isolat-
ed at different times from several rivers in the midwest.
Other tested rivers had ampicillin-resistant isolates that
were not imipenem-resistant (Figure). These rivers were
Arkansas (Little Rock), Canadian (Oklahoma City),
Hudson (New York), Chicago (Chicago), Colorado
(Glenwood Springs), Missouri (Parkville), Cuyahoga
(Cleveland), Mississippi (New Orleans, St. Louis), Ohio
(Cincinnati, Louisville, Pittsburgh, Wheeling), Platte
(Grand Island), Scioto (Columbus), Wabash (Terre Haute),
and White (Indianapolis). RAPD analysis was then
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isolates. Using a series of different primers, this genotyp-
ing technique identified clonally indistinguishable E.
asburiae isolates, although they were from various geo-
graphic origins (data not shown).
β β-Lactam Resistance Marker
The imipenem resistance marker was transferred from
each imipenem-resistant E. asburiae isolate to E. coli
DH10B by conjugation. Plasmid analysis identified a 66-
kb plasmid (pNat) from cultures of each imipenem-resist-
ant  E. asburiae isolate, whereas this plasmid was not
isolated from E. cloacae and E. asburiae reference strains
(data not shown). PCR experiments with primers for the
blaIMI-1 gene were positive with plasmid DNA of each E.
asburiae isolate and transconjugants as templates, where-
as primers designed to amplify blaNmcA and blaSme-1/Sme-2
failed to give PCR product. The Southern blot analysis
confirmed that the blaIMI-like gene was located on the nat-
ural plasmid pNat (data not shown).
Sequencing PCR products with primers hybridizing at
the ends of the blaIMI-1 gene and plasmid DNA of each
imipenem-resistant E. asburiae isolate identified the same
β-lactamase IMI-2 in all cases. This novel enzyme had 2
amino acid substitutions (tyrosine to histidine at position
Ambler 105 and asparagine to aspartic acid at position
Ambler 35) compared to the chromosomally encoded car-
bapenemase IMI-1 (5). β-Lactamase IMI-1 had been iso-
lated from an E. cloacae isolate from Minnesota close to
locations where IMI-2–producing isolates have been found
(5). However, the blaIMI-2 gene was not just a point-mutant
derivative of the blaIMI-1 gene, since these genes differ by
11 nucleotide substitutions. β-Lactamase IMI-2 was also
related to NmcA (97% amino acid identity) (8).
Cloning BamHI-restricted DNA of whole-cell DNA of
E. asburiae MS7 gave recombinant plasmid pIMI-2 that
had a 5.5-kb insert that allowed identification of the sur-
rounding sequence of the blaIMI-2 gene. A gene encoding a
LysR-type regulator named IMIR-2 was found just
upstream of blaIMI-2. It shared 95% amino acid identity
with IMIR-1, which is located upstream of the blaIMI-1
gene (5). The surrounding sequences of blaIMI-2 shared sig-
nificant nucleotide identity with transposable elements.
Part of an open reading frame that shared 97% nucleotide
identity with that of the transposase gene tnpA of the trans-
poson Tn2501 (Tn3 family) was identified downstream of
blaIMI-2 (33). Upstream of imiR-2, a 142-bp sequence
shared 76% nucleotide identity with part of the insertion
sequence IS2.
Susceptibility Testing and Expression of Resistance
MICs of several β-lactams, including carbapenems for
the IMI-2–positive E. asburiae MS7 and for E. coli
DH10B expressing the blaIMI-2 gene were high (Table 2).
The MICs of β-lactams for all imipenem-resistant clinical
isolates were identical (data not shown). Much higher level
of resistance to aztreonam than to expanded-spectrum
cephalosporins was found for the IMI-2–positive strains,
as reported for the other producers of class A carbapene-
mases (2). The activity of β-lactamase IMI-2 was partially
inhibited by clavulanate and tazobactam. Induction studies
showed increase of β-lactamase expression from 17- to 30-
fold (170 to 300 U/mg of protein) (for each E. asburiae
isolate when imipenem (50 mg/L) and cefoxitin (50 mg/L)
were used as inducers, respectively. These induction
results were consistent with location and functionality of a
LysR-type regulator gene upstream of the blaIMI-2 gene in
the imipenem-resistant E. asburiae isolates. No other
antimicrobial resistance marker was carried by natural
plasmid pNat.
Discussion
This report indicates that several U.S. rivers may be a
reservoir for broad-spectrum carbapenemases. Here, we
report a novel clavulanic-acid inhibited Ambler class A β-
lactamase IMI-2 that has an usual spectrum of hydrolysis
for this type of β-lactamase, including penicillins, car-
bapenems, and aztreonam (2). β-Lactamase IMI-2 is close-
ly related to several Ambler class Acarbapenemases whose
genes are chromosomally located, including blaIMI-1 and
blaNmcA, and found in several clinical isolates (5,8). While
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Figure. Sites of isolation of IMI-2–producing Enterobacter asburiae
isolates (black circles) and ampicillin-resistant, gram-negative rods
(white circles).this work was in progress, a clinical case of an NmcA-
producing  E. cloacae isolate was reported from Seattle
(34). An extended epidemiologic survey identified Sme-1
type–producing  Serratia marcescens isolates from the
West Coast to the East Coast, which indicates that these
isolates may also represent a reservoir for carbapenemases
in  Enterobacteriaceae (9). Thus, identification of car-
bapenemase genes in enterobacterial strains from rivers
may have clinical importance.
In the present study, the β-lactamase gene was plasmid-
encoded and was adjacent to mobile sequences that may
play an additional role in gene transfer. The E. asburiae
isolates were clonally related and may correspond to a sin-
gle clone, although they were obtained from distantly
related midwestern rivers. The reason for the presence of
these antimicrobial-resistant strains in this region is
unknown. Taking into account the small number of speci-
mens withdrawn from the rivers and the selection tech-
nique for imipenem-resistant isolates (ampicillin- and not
imipenem-containing plates), the prevalence of carbapene-
mase-producing enterobacterial strains may be high in the
environment, at least in the Midwest. 
Cloning experiments led to identification of a regulato-
ry gene from an E. asburiae strain (found in the other E.
asburiae strains as well [data not shown]) that explained
inducibility of carbapenemase expression. Whatever the
level of imipenem resistance is, failure of an imipenem-
containing regimen may occur when treating infections
caused by similar carbapenemase-producing strains, as
deduced from results obtained with an animal model of
pneumonia (35). Finally, this study raises the question of
the importance of this reservoir in Enterobacteriaceae as
well as the origin of this plasmid-located carbapenemase
gene that may be transferred among other enterobacterial
pathogens. 
Acknowledgement
We thank K. Bush for providing E. cloacae 1413B that pro-
duced the chromosome-encoded, clavulanate-inhibited carbapen-
emase IMI-1.
This work was funded by a grant from the Ministère de
l’Education Nationale et de la Recherche, (UPRES EA 3539)
Université Paris XI, Paris, France, and by the European
Community (6th PCRD, LSHM-CT-2003-503-335).
Dr. Aubron is studying antimicrobial resistance mechanisms
at the Hospital Bicêtre, South-Paris Medical School, University
Paris XI, France. She is a resident specializing in infectious dis-
eases. 
References
1. Lee EH, Nicolas MH, Kitzis MD, Pialoux G, Collatz E, Gutmann L.
Association of two resistance mechanisms in a clinical isolate of
Enterobacter cloacae with high level resistance to imipenem.
Antimicrob Agents Chemother. 1991;35:1093–8.
2. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative
aerobes. Clin Microbiol Infect. 2002;8:321–31.
3. De Champs C, Henquell C, Guelon D, Sirot D, Gazuy N, Sirot J.
Clinical and bacteriological study of nosocomial infections due to
Enterobacter aerogenes resistant to imipenem. J Clin Microbiol.
1993;31:123–7.
4. Nordmann P, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical
properties of a carbapenem-hydrolyzing β-lactamase from
Enterobacter cloacae and cloning of the gene into Escherichia coli.
Antimicrob Agents Chemother. 1993;37:939–46.
5. Rasmussen BA, Bush K, Keeney D, Yang Y, Hare R, O’Gara C, et al.
Characterization of IMI-1 β-lactamase, a class A carbapenem-
hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents
Chemother. 1996;40:2080–6.
6. Naas T, Livermore DM, Nordmann P. Characterization of an LysR
family protein, SmeR from Serratia marcescens S6, its effect on
expression of the carbapenem-hydrolyzing β-lactamase Sme-1, and
comparison of this regulator with other β-lactamase regulators.
Antimicrob Agents Chemother. 1995;39:629–37. 
Carbapenemase in Enterobacteriaceae, U.S. Rivers
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 2, February 2005 2637.  Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P.
Cloning and sequence analysis of the gene for a carbapenem-
hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens
S6. Antimicrob Agents Chemother. 1994;38:1262–70.
8. Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class A
β-lactamase from Enterobacter cloacae and of its LysR-type regula-
tory protein. Proc Natl Acad Sci U S A. 1994;91:7693–7.
9. Queenan AM, Torres-Vierra C, Gold HS, Carmeli Y, Eliopoulos GM,
Moellering Jr RC, et al. SME-type carbapenem-hydrolyzing class A
β-lactamases from geographically diverse Serratia marcescens
strains. Antimicrob Agents Chemother. 2000;44:3035–9.
10. Ambler RP, Coulson AF, Frère JM, Ghuyssen JM, Joris B, Forsman
M, et al. Astandard numbering scheme for the class Abeta-lactamase.
Biochem J. 1991;276:269–72.
11. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ,
Whichard JM. Imipenem resistance in Salmonella clinical strain due
to plasmid-mediated class A carbapenemase KPC-2. Antimicrob
Agents Chemother. 2003;47:1297–300.
12. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle
JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase,
KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2001;45:1151–61.
13. Smith-Moland E, Black JA, Ourada J, Reisbig MD, Hanson ND,
Thomson KS. Occurrence of newer β-lactamases in Klebsiella pneu-
moniae isolates from 24 U.S. hospitals. Antimicrob Agents
Chemother. 2002;46:3837–42. 
14. Smith-Moland E, Hanson ND, Herrera VL, Black AJ, Lockhart T,
Hossain A, et al. Plasmid-mediated, carbapenem-hydrolysing β-lacta-
mase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob
Chemother. 2003;51:711–4.
15.  Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG,
Nordmann P. GES-2, class A β-lactamase from Pseudomonas aerug-
inosa with increased hydrolysis of imipenem. Antimicrob Agents
Chemother. 2001;45:2598–603.
16. Sherwood L. Antimicrobial use in animal feed—time to stop. N Engl
J Med. 2001;345:1202–3.
17. White DG, Shaohua Z, Sudler R, Sherry A, Friedman S, Chen S, et al.
The isolation of antibiotic-resistant salmonella from retail ground
meats. N Engl J Med. 2001;345:1147–54.
18. Mac Arthur JV, Tuckfield RC. Spatial patterns in antibiotic resistance
among stream bacteria; effect of industrial pollution. Appl Environ
Microbiol. 2000;66:3722–6.
19. Munesia  M,  Garcia A, Miro E, Prats G, Jofre J, Navarro F.
Bacteriophages and diffusion of β-lactamase genes. Emerg Infect
Dis. 2004;10:1134–7.
20. Goni-Urriza M, Capdepuy M, Arpin C, Raymond N, Caumette P,
Quentin C. Impact of an urban effluent on antibiotic resistance of
riverine  Enterobacteriaceae and  Aeromonas spp. Appl Environ
Microbiol. 2000;66:125–32.
21. Baya AM, Brayton PR, Brown VL, Grimes DJ, Russek-Cohen E,
Colwell RR. Coincident plasmids and antimicrobial resistance in
marine bacteria isolated from polluted and unpolluted Atlantic Ocean
samples. Appl Environ Microbiol. 1986;51:1285–92.
22. Ash RJ, Mauck B, Morgan M. Antibiotic resistance of gram-negative
bacteria in rivers, United States. Emerg Infect Dis. 2002;8:713–6.
23. Brenner DJ, McWorther AC, Kai A, Steigerwalt AG, Farmer JJ.
Enterobacter asburiae sp. nov. a new species found in clinical speci-
mens and reassignement of Erwinia dissolvens and Erwinia nimi-
pressuralis to the genus Enterobacter as  Enterobacter dissolvens
comb. nov. and Enterobacter nimipressuralis comb. nov. J Clin
Microbiol. 1986;23:1114–20. 
24. Avidor B, Kletter Y, Abulafia S, Golan Y, Ephros M, Giladi M.
Molecular diagnosis of cat scratch disease: a two-step approach. J
Clin Microbiol. 1997;35:1924–30.
25. National Committee for Clinical Laboratory Standards. Methods for
dilution antimicrobial susceptibility tests for bacteria that grow aero-
bically. 6th ed. Approved standard M7-A5. Wayne (PA): The
Committee; 2003.
26. Poirel L, Guibert M, Bellais S, Naas T, Nordmann P. Integron- and
carbenicillinase-mediated reduced susceptibility to amoxicillin-
clavulanic acid in isolates of multidrug-resistant Salmonella enterica
serotype Typhimurium DT104 from French patients. Antimicrob
Agents Chemother. 1999;43:1098–104.
27. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P.
Molecular and biochemical characterization of VEB-1, a novel class
A extended-spectrum β-lactamase encoded by an Escherichia coli
integron gene. Antimicrob Agents Chemother. 1999;43:573–81.
28. Nazarowec-White M, Farber JM. Phenotypic and genotypic typing
food and clinical isolates of Enterobacter sakazakii. J Med Microbiol.
1999;48:559–67.
29. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA,
Tunnacliffe A. Degenerate oligonucleotide-primer PCR: general
amplification of target DNA by single degenerate primer. Genomics.
1992;13:718–25.
30. Kieser T. Factors affecting the isolation of CCC DNA from
Streptomyces lividans and Escherichia coli. Plasmid. 1984;12:19–36.
31. Danel F, Hall LM, Gur D, Livermore DM. OXA-14, another extend-
ed-spectrum variant of OXA-10 (PSE-2) β-lactamase from
Pseudomonas aeruginosa. Antimicrob Agents Chemother.
1995;39:1881–4. 
32. Churchward G, Belin D, Nagamine Y. A pSC101-derived plasmid
which shows no sequence homology to other commonly used cloning
vectors. Gene. 1984;31:165–71.
33. Michiels T, Cornelis G, Ellis K, Grinsted J. Tn2501, a component of
the lactose transposon Tn951, is an example of a new category of
class II transposable elements. J Bacteriol. 1987;169:624–31.
34. Pottumarthy S, Smith-Moland E, Juretschko S, Swanzy SR, Thomson
KS, Fritsche TR. NmcA carbapenem-hydrolyzing enzyme in
Enterobacter cloacae in North America. Emerg Infect Dis.
2003;9:999–1002
35. Mimoz O, Léotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O,
et al. Efficacies of imipenem, meropenem, cefepime, and ceftazidime
in rats with experimental pneumonia due to a carbapenem-hydrolyz-
ing  β-lactamase-producing strain of Enterobacter cloacae.
Antimicrob Agents Chemother. 2000;44:885–90.
Address for correspondence: Patrice Nordmann, Service de
Bactériologie-Virologie, Hôpital de Bicêtre, 78 Rue du Général Leclerc,
94275 Le Kremlin-Bicêtre, France; fax: 33-1-45-21-63-40; email: nord-
mann. patrice@bct.ap-hop-paris.fr
RESEARCH
264 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 2, February 2005
Search past issues of EID at www.cdc.gov/eid